APEX Ventures
VC Fund
Vienna, Austria
APEX Ventures is a deep-tech and medical-focused venture capital firm.
- Total investments:
- 53
- Last investment:
- Lead investor:
- 32%
Last updated:
For AI agents: llms.txt
Industries APEX Ventures invests in
Stages APEX Ventures invests in
Countries APEX Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Seed
- $1.4M–$8M
- Pre-Seed
- $552k–$9.1M
- Series A
- $2.4M–$22M
Investment Focus
Industry
- Artificial Intelligence 11 (21%)
- Software 10 (19%)
- Health Care 8 (15%)
- Biotechnology 7 (13%)
- Machine Learning 7 (13%)
Stage
- Seed 29 (55%)
- Series A 7 (13%)
- Pre-Seed 5 (9%)
- Venture - Series Unknown 2 (4%)
- Convertible Note 1 (2%)
Country
- Germany 14 (26%)
- United Kingdom 9 (17%)
- Austria 8 (15%)
- United States 2 (4%)
- Spain 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andreas Riegler
General Partner
|
General Partner | Total investments: 3 | Find email | |
Christoph Kanneberger
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 4 | Find email | |
Diana Röttger
Principal
|
Principal | Total investments: 1 | Find email | |
Jon M. Van Winkle
Principal
|
Principal | Total investments: 0 | Find email | |
Kelly Klein
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
HyperHeat
|
HyperHeat is building a cutting-edge, all-electric heating solution designed to reach temperatures of up to 2,000°C. Using renewable electricity HyperHeat is providing an efficient alternative to fossil fuel combustion. With an efficiency rate of up to 98%, HyperHeat is ideal for retrofitting industrial processes, enabling significant CO2reductions across industries like steel, cement, and chemicals. The scalable technology offers a cost-efficient approach to decarbonizing thermal processes, with a potential to reduce global CO2 emissions by over 4.5 gigatons annually. | $3.1M / Pre-Seed / Nov 26, 2024 | |
GEMESYS
|
Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny | $9.1M / Pre-Seed / Nov 19, 2024 | |
TriLite Technologies
|
TriLite Technologies is a developing world display tech for AR/VR applications. | $22M / Series A / Sep 11, 2024 | |
CardiaTec Biosciences
|
CardiaTec is a TechBio business that uses computational tools to unravel the biology underlying cardiovascular illness. CardiaTec uses massive and high-dimensional human omics data to better understand complicated disease biology and identify novel and differentiated therapies. | $6.5M / Seed / Sep 10, 2024 | |
|
Senisca
|
Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.7M / Seed / Mar 18, 2024 | |
Zetta Genomics
|
Zetta Genomics manages large-scale genomic data for precision medicine. The company employs distributed database technology and best practice security techniques to leverage genomic data benefits while preserving data privacy. Zetta Genomics was founded in 2018 and is based in Cambridge, England. | $2.3M / Seed / Feb 08, 2024 | |
sewts
|
Founded in 2019 and based in Munich, sewts GmbH provides cutting-edge perception software, pushing the boundaries of robotics in processing of easily deformable materials. sewts has developed and demonstrated a unique technology that uses high-precision finite element method (FEM) simulations to efficiently train machine learning algorithms. Theintelligent software solution enables countless applications in industrial automation like the handling of textiles in industrial laundries or the manufacturing of garment. sewts is backed by APEX Ventures, Bayern Kapital, High-Tech Gründerfonds, UnternehmerTUM Initiative for Industrial Innovators and a couple of highly experienced business angels. | $7.7M / Series A / Aug 09, 2023 | |
Upfront Diagnostics
|
Pockit has discovered and validated novel blood biomarkers for the detection of stroke patients suffering from a large vessel occlusion. Biomarkers enable faster and more accurate stroke diagnosis which will decrease the time to treatment, reducing disabilities and deaths after a stroke. Pockit owns a family of patents which protects novelbiomarkers for stroke detection. | $2M / Seed / Jun 27, 2023 | |
|
Zetta Genomics
|
Zetta Genomics manages large-scale genomic data for precision medicine. The company employs distributed database technology and best practice security techniques to leverage genomic data benefits while preserving data privacy. Zetta Genomics was founded in 2018 and is based in Cambridge, England. | $2.4M / Seed / Apr 17, 2023 | |
planqc
|
planqc's quantum computers store information in individual atoms – nature's best qubits. Quantum information is processed by arranging these qubits in highly scalable arrays and manipulating them with precisely controlled laser pulses. planqc’s unique combination of quantum technologies is the fastest way to scale to thousands of qubits,a prerequisite for industry-relevant quantum advantage. | Venture - Series Unknown / Feb 23, 2023 | |
| See all 53 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does APEX Ventures invest in?
APEX Ventures invests primarily in Artificial Intelligence, Software and Health Care startups, most often at Seed and Series A stage. Most of the 53 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is APEX Ventures's check size?
APEX Ventures typically joins rounds of $1.4M–$8M at Seed, $552k–$9.1M at Pre-Seed and $2.4M–$22M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds APEX Ventures participates in.
How do I contact APEX Ventures?
Public channels for APEX Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at APEX Ventures?
The team at APEX Ventures includes Andreas Riegler (General Partner), Christoph Kanneberger (Founder & Managing Partner) and Diana Röttger (Principal), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
